Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
Home | Login
About PhosphoSiteUsing PhosphoSiteprivacy & cookiesCuration ProcessContact
logos LINCs Logo Mt Sinai Logo NIH Logo NCI Logo
Search / Browse Functions
Curated Information Page
PubMed Id: 16513650 
Douillette A, et al. (2006) The proinflammatory actions of angiotensin II are dependent on p65 phosphorylation by the IkappaB kinase complex. J Biol Chem 281, 13275-84 16513650
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download Sites

S473-p - Akt1 (rat)
Modsite: RPHFPQFsYSASGTA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), vascular smooth muscle cell ('muscle, smooth')
Cellular systems studied:  cell lines
Species studied:  human, rat
Comments:  VSMC are rat not mouse cells.
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
angiotensin increase Ang II
LY294002 angiotensin inhibit treatment-induced increase

T203-p - ERK1 (rat)
Modsite: HDHTGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), vascular smooth muscle cell ('muscle, smooth')
Cellular systems studied:  cell lines
Species studied:  human, rat
Comments:  VSMC are rat not mouse cells.
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
angiotensin increase Ang II
U0126 angiotensin inhibit treatment-induced increase
siRNA angiotensin no effect upon treatment-induced increase IKKb siRNA

Y205-p - ERK1 (rat)
Modsite: HTGFLtEyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), vascular smooth muscle cell ('muscle, smooth')
Cellular systems studied:  cell lines
Species studied:  human, rat
Comments:  VSMC are rat not mouse cells.
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
angiotensin increase Ang II
U0126 angiotensin inhibit treatment-induced increase
siRNA angiotensin no effect upon treatment-induced increase IKKb siRNA

T183-p - ERK2 (rat)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), vascular smooth muscle cell ('muscle, smooth')
Cellular systems studied:  cell lines
Species studied:  human, rat
Comments:  VSMC are rat not mouse cells.
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
angiotensin increase Ang II
U0126 angiotensin inhibit treatment-induced increase
siRNA angiotensin no effect upon treatment-induced increase IKKb siRNA

Y185-p - ERK2 (rat)
Modsite: HtGFLtEyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), vascular smooth muscle cell ('muscle, smooth')
Cellular systems studied:  cell lines
Species studied:  human, rat
Comments:  VSMC are rat not mouse cells.
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
angiotensin increase Ang II
U0126 angiotensin inhibit treatment-induced increase
siRNA angiotensin no effect upon treatment-induced increase IKKb siRNA

S32-p - IkB-alpha (rat)
Modsite: LVDDRHDsGLDsMKD SwissProt Entrez-Gene
Orthologous residues
IkB‑alpha (human): S32‑p, IkB‑alpha (mouse): S32‑p, IkB‑alpha (rat): S32‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), vascular smooth muscle cell ('muscle, smooth')
Cellular systems studied:  cell lines
Species studied:  human, rat
Comments:  VSMC are rat not mouse cells.
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
angiotensin no change compared to control Ang II
TNF increase

S535-p - NFkB-p65 (rat)
Modsite: sGDEDFSsIADMDFS SwissProt Entrez-Gene
Orthologous residues
NFkB‑p65 (human): S536‑p, NFkB‑p65 (mouse): S534‑p, NFkB‑p65 (rat): S535‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), vascular smooth muscle cell ('muscle, smooth')
Cellular systems studied:  cell lines
Species studied:  human, rat
Comments:  VSMC are rat not mouse cells.
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
angiotensin increase Ang II
U0126 angiotensin no effect upon treatment-induced increase
PD98059 angiotensin no effect upon treatment-induced increase
angiotensin IKKB (rat) inhibit treatment-induced increase dominant negative IKKb (K44A)
siRNA angiotensin inhibit treatment-induced increase IKKb siRNA

S380-p - p90RSK (rat)
Modsite: HQLFRGFsFVATGLM SwissProt Entrez-Gene
Orthologous residues
p90RSK (human): S380‑p, p90RSK iso2 (human): S389‑p, p90RSK (mouse): S369‑p, p90RSK iso3 (mouse): , p90RSK (rat): S380‑p, p90RSK (chicken): S398‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), vascular smooth muscle cell ('muscle, smooth')
Cellular systems studied:  cell lines
Species studied:  human, rat
Comments:  VSMC are rat not mouse cells.
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
angiotensin increase Ang II
PD98059 angiotensin inhibit treatment-induced increase
U0126 angiotensin inhibit treatment-induced increase


Home  |  Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2017 Cell Signaling Technology, Inc.